BioCentury | Jan 5, 2018
Clinical News

Odonate starts Phase III trial of tesetaxel to treat breast cancer

...rights to tesetaxel from Daiichi Sankyo Co. Ltd. (Tokyo:4568). Tesetaxel was previously under development by Genta Inc....
BioCentury | Dec 14, 2017
Financial News

Odonate raises $150M IPO

...rights to tesetaxel from Daiichi Sankyo Co. Ltd. (Tokyo:4568). Tesetaxel was previously under development by Genta Inc....
BioCentury | Dec 8, 2017
Financial News

Odonate down after $150M IPO

...rights to tesetaxel from Daiichi Sankyo Co. Ltd. (Tokyo:4568). Tesetaxel was previously under development by Genta Inc....
BioCentury | Nov 17, 2017
Financial News

Odonate proposes $172.5M IPO

...rights to tesetaxel from Daiichi Sankyo Co. Ltd. (Tokyo:4568). Tesetaxel was previously under development by Genta Inc....
...see BioCentury, Aug. 6, 2012 ). Odonate Therapeutics LLC, San Diego, Calif. Mary Romeo tesetaxel Daiichi Sankyo Co. Ltd. Genta Inc. Odonate...
BioCentury | Aug 6, 2012
Company News

Genta cancer news

...and a three-month net operating cash burn of $1.3 million. In its 1Q12 earnings statement, Genta...
...of funds during June. The company was founded in 1988, but has never been profitable. Genta...
...compound is tesetaxel, which is in Phase II testing to treat various types of cancer. Genta...
BioCentury | Aug 3, 2012
Company News

Genta files for Chapter 7 bankruptcy

...Cancer company Genta Inc. (OTCBB:GNTA) said it intends to file for Chapter 7 bankruptcy in the U.S...
...and a three-month net operating cash burn of $1.3 million. In its 1Q12 earnings statement, Genta...
...of funds during June. The company was founded in 1988, but has never been profitable. Genta...
BioCentury | Jun 25, 2012
Clinical News

Tesetaxel: SPA received

...and that PFS, rather than overall survival (OS), will be used as a primary endpoint. Genta...
...to treat advanced gastric cancer and Orphan Drug designation in the U.S. to treat melanoma. Genta...
...Sankyo in 2008 (see BioCentury, March 10, 2008). Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda. Genta Inc....
BioCentury | Jun 11, 2012
Clinical News

Tesetaxel: Phase IIb started

...to treat advanced gastric cancer and Orphan Drug designation in the U.S. to treat melanoma. Genta...
...Sankyo in 2008 (see BioCentury, March 10, 2008). Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda. Genta Inc....
BioCentury | Jun 4, 2012
Clinical News

Tesetaxel: Additional Phase IIb data

...was neutropenia. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Genta...
...details. Genta licensed the product from Daiichi Sankyo in 2008 (see BioCentury, March 10, 2008). Genta Inc....
BioCentury | May 14, 2012
Clinical News

Tesetaxel: Phase II started

...to treat advanced gastric cancer and Orphan Drug designation in the U.S. to treat melanoma. Genta...
...in 2008 (see BioCentury, March 10, 2008). Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda capecitabine. Genta Inc....
Items per page:
1 - 10 of 493
BioCentury | Jan 5, 2018
Clinical News

Odonate starts Phase III trial of tesetaxel to treat breast cancer

...rights to tesetaxel from Daiichi Sankyo Co. Ltd. (Tokyo:4568). Tesetaxel was previously under development by Genta Inc....
BioCentury | Dec 14, 2017
Financial News

Odonate raises $150M IPO

...rights to tesetaxel from Daiichi Sankyo Co. Ltd. (Tokyo:4568). Tesetaxel was previously under development by Genta Inc....
BioCentury | Dec 8, 2017
Financial News

Odonate down after $150M IPO

...rights to tesetaxel from Daiichi Sankyo Co. Ltd. (Tokyo:4568). Tesetaxel was previously under development by Genta Inc....
BioCentury | Nov 17, 2017
Financial News

Odonate proposes $172.5M IPO

...rights to tesetaxel from Daiichi Sankyo Co. Ltd. (Tokyo:4568). Tesetaxel was previously under development by Genta Inc....
...see BioCentury, Aug. 6, 2012 ). Odonate Therapeutics LLC, San Diego, Calif. Mary Romeo tesetaxel Daiichi Sankyo Co. Ltd. Genta Inc. Odonate...
BioCentury | Aug 6, 2012
Company News

Genta cancer news

...and a three-month net operating cash burn of $1.3 million. In its 1Q12 earnings statement, Genta...
...of funds during June. The company was founded in 1988, but has never been profitable. Genta...
...compound is tesetaxel, which is in Phase II testing to treat various types of cancer. Genta...
BioCentury | Aug 3, 2012
Company News

Genta files for Chapter 7 bankruptcy

...Cancer company Genta Inc. (OTCBB:GNTA) said it intends to file for Chapter 7 bankruptcy in the U.S...
...and a three-month net operating cash burn of $1.3 million. In its 1Q12 earnings statement, Genta...
...of funds during June. The company was founded in 1988, but has never been profitable. Genta...
BioCentury | Jun 25, 2012
Clinical News

Tesetaxel: SPA received

...and that PFS, rather than overall survival (OS), will be used as a primary endpoint. Genta...
...to treat advanced gastric cancer and Orphan Drug designation in the U.S. to treat melanoma. Genta...
...Sankyo in 2008 (see BioCentury, March 10, 2008). Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda. Genta Inc....
BioCentury | Jun 11, 2012
Clinical News

Tesetaxel: Phase IIb started

...to treat advanced gastric cancer and Orphan Drug designation in the U.S. to treat melanoma. Genta...
...Sankyo in 2008 (see BioCentury, March 10, 2008). Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda. Genta Inc....
BioCentury | Jun 4, 2012
Clinical News

Tesetaxel: Additional Phase IIb data

...was neutropenia. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Genta...
...details. Genta licensed the product from Daiichi Sankyo in 2008 (see BioCentury, March 10, 2008). Genta Inc....
BioCentury | May 14, 2012
Clinical News

Tesetaxel: Phase II started

...to treat advanced gastric cancer and Orphan Drug designation in the U.S. to treat melanoma. Genta...
...in 2008 (see BioCentury, March 10, 2008). Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda capecitabine. Genta Inc....
Items per page:
1 - 10 of 493